NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $11.31 +0.04 (+0.39%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xencor Stock (NASDAQ:XNCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xencor alerts:Sign Up Key Stats Today's Range$11.26▼$11.6250-Day Range$10.41▼$13.1052-Week Range$6.92▼$18.69Volume124,115 shsAverage Volume779,334 shsMarket Capitalization$838.82 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingHold Company Overview Xencor, Inc. is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins. The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics. Xencor’s pipeline features multiple clinical-stage candidates, including bispecific molecules that recruit T cells to tumor cells and antibody therapeutics targeting checkpoint pathways. The company also explores next-generation cytokine fusions designed to improve safety and efficacy profiles over conventional formats. In advancing its discovery programs, Xencor has established strategic collaborations and licensing agreements with several leading pharmaceutical companies. Partners include Amgen, Pfizer, AstraZeneca and Lilly, among others, which leverage Xencor’s XmAb® platform to generate novel candidates across oncology, inflammation and immunology. Through these partnerships, Xencor’s technology reaches global markets via co-development and commercial licensing arrangements. Founded in 1997 and headquartered in Monrovia, California, Xencor is led by President and Chief Executive Officer Bassil Dahiyat, Ph.D., who co-founded the company with a vision to harness protein engineering for therapeutic innovation. Over its history, Xencor has grown from a technology-focused startup into a specialized biotech organization advancing multiple clinical programs toward regulatory milestones.AI Generated. May Contain Errors. Read More Xencor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreXNCR MarketRank™: Xencor scored higher than 44% of companies evaluated by MarketBeat, and ranked 618th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingXencor has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialXencor has a consensus price target of $24.50, representing about 116.7% upside from its current price of $11.31.Amount of Analyst CoverageXencor has only been the subject of 4 research reports in the past 90 days.Read more about Xencor's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.82) to ($3.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.98% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 15.62, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 2.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.75 News SentimentXencor has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xencor this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $499,817.00 in company stock.Percentage Held by Insiders4.76% of the stock of Xencor is held by insiders.Percentage Held by InstitutionsXencor has minimal institutional ownership at this time.Read more about Xencor's insider trading history. Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XNCR Stock News HeadlinesXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Xencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comJPMorgan Chase & Co. Issues Positive Forecast for Xencor (NASDAQ:XNCR) Stock PriceMay 12, 2026 | americanbankingnews.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comXencor Reports First Quarter 2026 Financial ResultsMay 6, 2026 | businesswire.comSee More Headlines XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $15.31 on January 1st, 2026. Since then, XNCR stock has decreased by 26.2% and is now trading at $11.3050. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.96. Xencor's revenue for the quarter was down 86.2% compared to the same quarter last year. When did Xencor IPO? Xencor (XNCR) raised $70 million in an initial public offering on Tuesday, December 3rd 2013. The company issued 12,730,000 shares at $5.50 per share. Who are Xencor's major shareholders? Xencor's top institutional shareholders include EcoR1 Capital LLC (2.94%), Dimensional Fund Advisors LP (1.75%), Bank of New York Mellon Corp (0.53%) and Bank of America Corp DE (0.49%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Celia Eckert, Nancy Valente, Alan Bruce Montgomery, Kurt A Gustafson, Richard J Ranieri and Ellen Feigal. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/06/2026Today5/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 XNCR's financial health is in the Red zone, according to TradeSmith. XNCR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XNCR CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year Founded1997Price Target and Rating Average Price Target for Xencor$24.50 High Price Target$42.00 Low Price Target$12.00 Potential Upside/Downside+117.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$91.92 million Net Margins-177.10% Pretax Margin-174.61% Return on Equity-28.77% Return on Assets-20.52% Debt Debt-to-Equity RatioN/A Current Ratio6.57 Quick Ratio6.57 Sales & Book Value Annual Sales$125.58 million Price / Sales6.66 Cash FlowN/A Price / Cash FlowN/A Book Value$6.95 per share Price / Book1.62Miscellaneous Outstanding Shares74,140,000Free Float70,613,000Market Cap$836.30 million OptionableOptionable Beta0.93 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:XNCR) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
